Eric Schulze – CEO, Lifetrack Medical Systems
Lifetrack Medical Systems’ Dr Eric Schulze explores the origins of his company, how its software platform has the potential to revolutionise radiology workflows in Asia and beyond, and the barriers…
Address: 41 Science Park Road, #04-03B The Gemini,Singapore Science Park II,Singapore 117610,Singapore
Tel: +(65) 6829-5600
Web: http://www.merlionpharma.com/
MerLion Pharmaceuticals Pte Ltd was formed in 2002 through the privatisation of the former Centre for Natural Product Research (CNPR), a unique unit of Singapore’s Institute of Molecular and Cell Biology (IMCB). MerLion Pharma acquired all of CNPR’s assets, including its unique collection of natural product samples. The company is now focused on developing its lead antibacterial candidate, finafloxacin.
MerLion Pharma is progressing finafloxacin, a novel, highly differentiated antibacterial candidate. The compound, which has already shown potential for the treatment of urinary tract infections and the eradication of Helicobacter pylori, is being evaluated in critical care and hospital indications
Lifetrack Medical Systems’ Dr Eric Schulze explores the origins of his company, how its software platform has the potential to revolutionise radiology workflows in Asia and beyond, and the barriers…
Industry veteran Marine Queniart-Stojanovic, a self-described “global citizen with a French passport,” currently serves as Sanofi’s GM for general medicines in Thailand, Malaysia, and Singapore. With Sanofi undergoing a significant…
Alan Goh of NDR Medical Technology, a pioneer in intelligent navigation and image processing for minimally invasive surgery, introduces the progress of the company to date, how its technology has…
Singapore is one of the healthiest countries in Asia with a life expectancy in excess of 82 years buttressed by one of the most robust healthcare apparatuses in the world.…
IQVIA Biotech JAPAC’s Dr Senthil Sockalingam outlines the evolving needs of the flood of early-stage drug discovery ventures in Asia, how biotechs in the region differ from their counterparts in…
Singapore recently outlined its latest Research, Innovation and Enterprise (RIE) 2025 plan, with plans to invest some USD 20 billion over the next 5 years. Here, three key stakeholders from…
Industry veteran Marine Queniart-Stojanovic outlines the significance of the Thailand-Malaysia-Singapore country grouping to Sanofi’s APAC operations; how the company’s global rationalisation and prioritisation push has been reflected at the country…
Professor Ashok Venkitaraman introduces his work in Singapore, coordinating and catalysing research on the causes of cancer in Asia, and translating this research to clinical impact through improved detection, treatment…
Erika Pagani, country manager for Pfizer Singapore, shares her journey with the company from Brazil to New York, Peru, Ecuador, and finally Singapore. She discusses why the island city-state is…
Beh Kian Teik of Singapore’s National Research Foundation (NRF) outlines the importance of the life sciences within the country’s innovation strategy and the role it has to play at a…
EY’s Abhay Bangi highlights the key trends across the ASEAN life sciences space, how the COVID-19 pandemic has accelerated them, and charts Singapore’s course towards becoming a world-class biotech investment…
Innovation is at the heart of healthcare transformation and the doors for a much-needed shift from provider- to patient-centric solutions have been opened. That is the idea behind HealthBeats™, a…
See our Cookie Privacy Policy Here
